carmoterol has been researched along with indacaterol in 3 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (33.33) | 29.6817 |
2010's | 2 (66.67) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Baur, F; Beattie, D; Beer, D; Bentley, D; Bradley, M; Bruce, I; Charlton, SJ; Cuenoud, B; Ernst, R; Fairhurst, RA; Faller, B; Farr, D; Fozard, JR; Fullerton, J; Garman, S; Hatto, J; Hayden, C; He, H; Howes, C; Janus, D; Jiang, Z; Keller, T; Lewis, C; Loeuillet-Ritzler, F; Moser, H; Reilly, J; Steward, A; Sykes, D; Tedaldi, L; Trifilieff, A; Tweed, M; Watson, S; Wissler, E; Wyss, D | 1 |
Cazzola, M; Matera, MG | 1 |
PÅ‚usa, T | 1 |
1 review(s) available for carmoterol and indacaterol
Article | Year |
---|---|
ultra-long-acting beta2-adrenoceptor agonists: an emerging therapeutic option for asthma and COPD?
Topics: Adrenergic beta-2 Receptor Agonists; Adrenergic beta-Agonists; Amphetamines; Animals; Asthma; Bronchodilator Agents; Ethanolamines; Formoterol Fumarate; Humans; Hydroxyquinolines; Indans; Pulmonary Disease, Chronic Obstructive; Quinolones | 2007 |
2 other study(ies) available for carmoterol and indacaterol
Article | Year |
---|---|
The identification of indacaterol as an ultralong-acting inhaled beta2-adrenoceptor agonist.
Topics: Administration, Inhalation; Adrenergic beta-2 Receptor Agonists; Animals; Bronchodilator Agents; Guinea Pigs; Humans; Hydrophobic and Hydrophilic Interactions; Indans; Quinolones; Structure-Activity Relationship | 2010 |
[Novel controllers of airway obstruction in COPD patients].
Topics: Airway Obstruction; Amphetamines; Bronchodilator Agents; Drug Administration Schedule; Drug Combinations; Humans; Hydroxyquinolines; Indans; Muscarinic Antagonists; Patient Compliance; Pulmonary Disease, Chronic Obstructive; Quinolones | 2011 |